{"id":11128,"date":"2026-11-01T09:20:00","date_gmt":"2026-11-01T14:20:00","guid":{"rendered":"https:\/\/www.inflation.us\/news\/?p=11128"},"modified":"2026-11-01T11:00:15","modified_gmt":"2026-11-01T16:00:15","slug":"trumprx-could-become-much-bigger-than-anyone-imagines","status":"publish","type":"post","link":"https:\/\/www.inflation.us\/news\/articles\/trumprx-could-become-much-bigger-than-anyone-imagines\/","title":{"rendered":"TrumpRx Could Become Much Bigger Than Anyone Imagines"},"content":{"rendered":"\n<div style=\"width:100%; max-width:650px; margin:0 auto; padding:0 10px; box-sizing:border-box; font-family:Arial,Helvetica,sans-serif; font-size:14px; line-height:1.6; color:#333333; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%; text-size-adjust:100%; mso-line-height-rule:exactly; display:block;\">\n<h2>TrumpRx and Cost Plus Drugs Are Reshaping How Americans Shop for Prescriptions<\/h2>\n\n<p>Two of the <strong><span style=\"color:#27ae60;\">biggest<\/span> recent stories<\/strong> in U.S. prescription drug pricing are the <span style=\"color:#27ae60;\"><strong>launch<\/strong><\/span> of <strong>President Donald Trump&#39;s TrumpRx.gov<\/strong> and the <span style=\"color:#27ae60;\"><strong>rapid growth<\/strong><\/span> of <strong>Mark Cuban&#39;s Cost Plus Drugs<\/strong>.<\/p>\n\n<p>The two men are <strong>political <span style=\"color:#e74c3c;\">opposites<\/span><\/strong>. Even so, both are <span style=\"color:#2980b9;\"><strong>pushing the same idea<\/strong><\/span>: patients should be able to see <span style=\"color:#27ae60;\"><strong>cash prices<\/strong><\/span> and <span style=\"color:#2980b9;\"><strong>compare<\/strong><\/span> them.<\/p>\n\n<p><strong>The numbers so far<\/strong><\/p>\n\n<ul>\n\t<li><strong>TrumpRx<\/strong> <span style=\"color:#27ae60;\"><strong>launched<\/strong><\/span> on February 5, 2026 with about <strong>40 drugs<\/strong>. After <span style=\"color:#27ae60;\"><strong>two expansions<\/strong><\/span> in May and June, it lists <span style=\"color:#27ae60;\"><strong>more than<\/strong><\/span> <strong>800 generics<\/strong>, in addition to its <span style=\"color:#2980b9;\"><strong>brand-name<\/strong><\/span> offerings.<\/li>\n\t<li><strong>Cost Plus Drugs<\/strong> <span style=\"color:#27ae60;\"><strong>launched<\/strong><\/span> in January 2022 with <strong>111 medications<\/strong>. It now <span style=\"color:#2980b9;\"><strong>offers<\/strong><\/span> <strong>thousands<\/strong> of products.<\/li>\n<\/ul>\n\n<p>The two <span style=\"color:#e74c3c;\"><strong>aren&#39;t<\/strong><\/span> really <span style=\"color:#e74c3c;\"><strong>competitors<\/strong><\/span>. In May, <strong>TrumpRx<\/strong> began <strong><span style=\"color:#2980b9;\">integrating<\/span> prices<\/strong> from <strong>Cost Plus Drugs<\/strong>, <strong>Amazon Pharmacy<\/strong> and <strong>GoodRx<\/strong>. It sometimes <strong><span style=\"color:#27ae60;\">routes<\/span> users<\/strong> <span style=\"color:#2980b9;\"><strong>directly<\/strong><\/span> to those services. <strong>TrumpRx<\/strong> is <span style=\"color:#e74c3c;\"><strong>not<\/strong><\/span> a <strong>pharmacy<\/strong> itself. It <strong><span style=\"color:#2980b9;\">points<\/span> patients<\/strong> to <strong>manufacturers&#39; <span style=\"color:#2980b9;\">direct-to-consumer<\/span> sites<\/strong>, <strong>coupons<\/strong> and <strong>partner pharmacies<\/strong>.<\/p>\n\n<h2>Where Medicure&#39;s Marley Drug Fits In<\/h2>\n\n<p>Other companies are also competing for <strong><span style=\"color:#27ae60;\">cash-paying<\/span> prescription customers<\/strong>. One is <strong>Medicure Inc. (TSXV: MPH)<\/strong>, which <span style=\"color:#27ae60;\"><strong>owns<\/strong><\/span> <strong>Marley Drug<\/strong>, a <strong><span style=\"color:#2980b9;\">licensed<\/span> U.S. mail-order pharmacy<\/strong> that <strong><span style=\"color:#27ae60;\">serves<\/span> patients <span style=\"color:#2980b9;\">nationwide<\/span><\/strong>.<\/p>\n\n<h3>Case study: LODOCO&reg; (low-dose colchicine)<\/h3>\n\n<p><strong>LODOCO<\/strong> was <span style=\"color:#27ae60;\"><strong>approved<\/strong><\/span> by the <strong>FDA<\/strong> in 2023. It was the <strong><span style=\"color:#2980b9;\">first<\/span> <span style=\"color:#e74c3c;\">anti-inflammatory<\/span> drug <span style=\"color:#27ae60;\">approved<\/span><\/strong> in the U.S. to <span style=\"color:#e74c3c;\"><strong>reduce the risk<\/strong><\/span> of <strong>cardiovascular events<\/strong> such as heart attack and stroke in eligible adults. In the LoDoCo2 trial, low-dose colchicine was associated with a relative reduction of about 31% in the primary composite cardiovascular endpoint compared with placebo.<\/p>\n\n<p>Prices for <strong>LODOCO<\/strong> vary widely by pharmacy. We <span style=\"color:#2980b9;\"><strong>compared<\/strong><\/span> the <span style=\"color:#27ae60;\"><strong>cash price<\/strong><\/span> of <strong>LODOCO 0.5 mg<\/strong> (30 tablets) on November 1st, 2026:<\/p>\n\n<table>\n\t<thead>\n\t\t<tr>\n\t\t\t<th>Pharmacy<\/th>\n\t\t\t<th>Price without insurance<\/th>\n\t\t<\/tr>\n\t<\/thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td>Amazon Pharmacy<\/td>\n\t\t\t<td>$578 ($332.45 with Prime prescription savings)<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td>GoodRx<\/td>\n\t\t\t<td>$501.93 (listed retail price about $637)<\/td>\n\t\t<\/tr>\n\t\t<tr>\n\t\t\t<td><strong>Marley Drug<\/strong><\/td>\n\t\t\t<td><strong>$79, with free shipping<\/strong><\/td>\n\t\t<\/tr>\n\t<\/tbody>\n<\/table>\n\n<p>The manufacturer, <strong>Agepha Pharma<\/strong>, names <strong>Marley Drug<\/strong> and <strong>BlinkRx<\/strong> as mail-order options for <strong>LODOCO<\/strong>. According to Agepha, eligible commercially insured patients may pay as little as $10 per month. Eligibility rules and restrictions apply.<\/p>\n\n<h3>Marley Drug also works with other platforms<\/h3>\n\n<p><strong>Marley Drug<\/strong> <span style=\"color:#e74c3c;\"><strong>does not<\/strong><\/span> <span style=\"color:#2980b9;\"><strong>rely only<\/strong><\/span> on <strong>direct customers<\/strong> at MarleyDrug.com. <strong>Medicure<\/strong> has announced a <span style=\"color:#2980b9;\"><strong>partnership<\/strong><\/span> with the prescription savings platform <strong>RxSpark<\/strong>, under which <strong>Marley Drug<\/strong> is the <strong><span style=\"color:#2980b9;\">exclusive<\/span> mail-order pharmacy<\/strong>. This shows that <strong>Marley<\/strong> can <strong><span style=\"color:#27ae60;\">fulfill<\/span> prescriptions<\/strong> for other healthcare businesses, <span style=\"color:#e74c3c;\"><strong>not just<\/strong><\/span> its <strong>own customers<\/strong>.<\/p>\n\n<h2>Could Marley Drug Join TrumpRx?<\/h2>\n\n<p><strong>TrumpRx<\/strong> <strong><span style=\"color:#2980b9;\">already <\/span><span style=\"color:#27ae60;\">draws<\/span> pricing<\/strong> from <strong>Cost Plus Drugs<\/strong>, <strong>Amazon Pharmacy<\/strong> and <strong>GoodRx<\/strong>. That raises the question of whether other pharmacies could be added as the platform expands.<\/p>\n\n<p><strong><span style=\"color:#e74c3c;\">No<\/span> <span style=\"color:#2980b9;\">partnership<\/span> between TrumpRx and Medicure (TSXV: MPH) has been announced, and there is no assurance one will happen.<\/strong> If <strong>TrumpRx<\/strong> <span style=\"color:#2980b9;\"><strong>does partner<\/strong><\/span> with <strong>Medicure<\/strong> we would expect <strong>MPH shares<\/strong> to become the <span style=\"color:#27ae60;\"><strong>#1 largest percentage gainer <\/strong><\/span>of 2027. <strong>Marley&#39;s <span style=\"color:#2980b9;\">existing fulfillment infrastructure<\/span><\/strong>, <strong><span style=\"color:#e74c3c;\">low<\/span> <span style=\"color:#27ae60;\">cash price<\/span><\/strong> on <strong>LODOCO<\/strong> and <span style=\"color:#2980b9;\"><strong>experience<\/strong><\/span> with <strong>third-party platforms<\/strong> make it the <strong><span style=\"color:#27ae60;\">#1 top<\/span> healthcare company<\/strong> to <span style=\"color:#2980b9;\"><strong>watch<\/strong><\/span> going into 2027.<\/p>\n\n<p style=\"margin:0 0 16px; padding:0; font-family:Arial,Helvetica,sans-serif; font-size:8px; line-height:1.5; color:#555555;\"><em>Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA&#39;s President has purchased 87,000 shares of MPH and intends to buy more shares. This message is meant for informational and educational purposes only.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>TrumpRx and Cost Plus Drugs Are Reshaping How Americans Shop for Prescriptions Two of the biggest recent stories in U.S. prescription drug pricing are the launch of President Donald Trump&#39;s TrumpRx.gov and the rapid growth of Mark Cuban&#39;s Cost Plus Drugs. The two men are political opposites. Even so, both are pushing the same idea: [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":11132,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[365,414,26,8],"class_list":["post-11128","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-biotech","tag-mph","tag-politics","tag-technology"],"_links":{"self":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/comments?post=11128"}],"version-history":[{"count":1,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11128\/revisions"}],"predecessor-version":[{"id":11130,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/posts\/11128\/revisions\/11130"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media\/11132"}],"wp:attachment":[{"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/media?parent=11128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/categories?post=11128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.inflation.us\/news\/wp-json\/wp\/v2\/tags?post=11128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}